These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2004-000232-91 EICH Profilaxis con ATeGe-FRESENIUS en trasplante alogénico de progenitores hematopoyéticos procedente de donantes no emparentados 2015-02-26 bad-data
Not reported 2004-000723-15 Two-arm, randomized (2:1), open-label phase II/III study in EpCAM positive cancer patients with symptomatic malignant ascites using paracentesis plus the tri-functional antibody removab (anti-EpCAM x ... 2006-11-02 due-trials
Not reported 2005-001131-30 A Double-Blind, Placebo-Controlled, Multicenter, Dose-ranging Study of an Anti-T-lymphocyte Immunglobuline (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Pr... 2011-01-25 due-trials
Not reported 2005-001700-39 Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cancer p... 2006-11-07 due-trials
Not reported 2005-004294-21 Estudio de fase II del anticuerpo trifuncional anti-HER-2/neu x anti-CD3 ertumaxomab en pacientes con cáncer de mama avanzado o metastásico resistente al tratamiento hormonal que expresa HER­2/neu 1+ ... 2009-02-03 due-trials
Listed as ongoing, but also has a completion date 2005-004431-21 Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilizaci... 2010-04-29 bad-data
Not reported 2005-005945-20 Multicenter, open-label and randomized phase II study to evaluate safety and efficacy of the tri-functional bispecific antibody catumaxomab(anti-EpCAM x anti-CD3) in patients after curative resection ... 2009-06-22 due-trials
Listed as ongoing, but also has a completion date 2006-002727-16 Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma after n... 2013-04-26 bad-data
Not reported 2006-004484-54 Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer 2008-08-08 due-trials
Listed as ongoing, but also has a completion date 2006-005017-36 Phase II study for repeated dosing of the trifunctional bispecific anti-HER-2/neu x anti-CD3 antibody ertumaxomab in patients with HER-2/neu 1+ or 2+/FISH negative expressing advanced or metastatic ... 2009-02-03 bad-data
Completed, report not yet due 2006-006694-24 Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia 2009-02-03 not-yet-due
Completed, but no date 2007-005261-35 Treatment of Graves’ Orbitopathy (GO) with ATG-Fresenius: A prospective, randomized, open, controlled phase II study to assess the efficacy and safety of an add-on ATG-Fresenius treatment versus a sta... bad-data
Listed as ongoing, but also has a completion date 2008-001557-17 Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites due t... 2011-04-26 bad-data
Listed as ongoing, but also has a completion date 2009-014076-22 Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after tr... 2011-05-10 bad-data